Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-1103a + trastuzumab deruxtecan
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**DS-1103a + trastuzumab deruxtecan** is an investigational combination therapy currently in early clinical evaluation for advanced solid tumors. DS-1103a is a recombinant humanized IgG4 monoclonal antibody targeting signal regulatory protein alpha (SIRPα), designed to block the SIRPα-CD47 immune checkpoint pathway and promote phagocytosis of tumor cells. Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that combines a human monoclonal antibody against HER2 (human epidermal growth factor receptor 2) with a topoisomerase I inhibitor payload via a cleavable linker. This combination aims to maximize anti-tumor immune activity by unblocking macrophage phagocytosis (via SIRPα inhibition) and delivering targeted cytotoxicity to HER2-expressing or HER2-mutant cancer cells (via T-DXd’s ADC mechanism). The development is led by Daiichi Sankyo and involves collaborations with AstraZeneca.
- Other names
- trastuzumab deruxtecanDS-8201aDS8201aDS 8201a
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)SIRPA (Signal-regulatory protein alpha)
Beyond the preview
Go deeper on DS-1103a + trastuzumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-1103a + trastuzumab deruxtecan.